<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya</journal-id>
      <journal-id journal-id-type="publisher-id">.</journal-id>
      <journal-title>Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya</journal-title><issn pub-type="ppub">2621-4814</issn><issn pub-type="epub">2621-4814</issn><publisher>
      	<publisher-name>Institute for Research and Community Services Universitas Muhammadiyah Palangkaraya</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.33084/bjop.v7i1.6334</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group><subject>Pharmacovigilance</subject><subject>Pharmacist</subject><subject>Reliability</subject><subject>Spontaneous reporting</subject><subject>Validity</subject></subj-group>
      </article-categories>
      <title-group>
        <article-title>Development and Validation of a Questionnaire for the Assessment of the Factors that Influence ADR Reporting by Pharmacists</article-title><subtitle>Development and Validation of a Questionnaire for the Assessment of the Factors that Influence ADR Reporting by Pharmacists</subtitle></title-group>
      <contrib-group><contrib contrib-type="author">
	<name name-style="western">
	<surname>Firdaus</surname>
		<given-names>Favian Rafif</given-names>
	</name>
	<aff>Master of Pharmaceutical Sciences Program, Universitas Airlangga, Surabaya, East Java, Indonesia</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Nita</surname>
		<given-names>Yunita</given-names>
	</name>
	<aff>Department of Pharmacy Practice, Universitas Airlangga, Surabaya, East Java, Indonesia</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Setiawan</surname>
		<given-names>Catur Dian</given-names>
	</name>
	<aff>Department of Pharmacy Practice, Universitas Airlangga, Surabaya, East Java, Indonesia</aff>
	</contrib><contrib contrib-type="author">
	<name name-style="western">
	<surname>Zairina</surname>
		<given-names>Elida</given-names>
	</name>
	<aff>Department of Pharmacy Practice, Universitas Airlangga, Surabaya, East Java, Indonesia</aff>
	</contrib></contrib-group>		
      <pub-date pub-type="ppub">
        <month>02</month>
        <year>2024</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>02</month>
        <year>2024</year>
      </pub-date>
      <volume>7</volume>
      <issue>1</issue>
      <permissions>
        <copyright-statement>© 2024 Favian Rafif Firdaus, Yunita Nita, Catur Dian Setiawan, Elida Zairina</copyright-statement>
        <copyright-year>2024</copyright-year>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-sa/4.0/"><p>This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.</p></license>
      </permissions>
      <related-article related-article-type="companion" vol="2" page="e235" id="RA1" ext-link-type="pmc">
			<article-title>Development and Validation of a Questionnaire for the Assessment of the Factors that Influence ADR Reporting by Pharmacists</article-title>
      </related-article>
	  <abstract abstract-type="toc">
		<p>
			Drug safety is a significant concern in many countries, as side effects (AE) and adverse drug reactions (ADR) have caused many deaths worldwide. One of the reasons is the low contribution of pharmacists in spontaneously reporting AE ADR. This study aims to develop a questionnaire to assess factors that correlate with spontaneous reporting by pharmacists. A questionnaire pilot was tested on 30 pharmacist respondents who worked in type C hospitals in Surabaya and Sidoarjo, Indonesia. Respondents responses were then evaluated for face validity, construct validity, and reliability. The results showed that the face validity of the questionnaire was ideal. Then, the results of the construct validity of the knowledge section using point biserial correlation showed that two items were invalid because the r value was smaller than the r table (r was 0.361). Then, construct validity uses the factor analysis method for psychological, environmental, and practical variables by paying attention to the Kaiser-Mayer-Olkin Measure (KMO) value, which must be greater than 0.5, the significance of the Bartlett test, which must be less than 0.05 and the factor loading value which conditions must be greater than 0.5. As a result, most of the psychological, environmental, and practical variables show valid and reliable results. However, further consideration should be given to eliminating some items that do not meet the requirements. In conclusion, this validated questionnaire can be used to obtain additional information regarding factors influencing spontaneous reporting by pharmacists.
		</p>
		</abstract>
    </article-meta>
  </front>
  <body><sec>
			<title>INTRODUCTION</title>
				<p >Drug safety is
a significant concern in several countries, monitored and evaluated through
pharmacovigilance systems. Pharmacovigilance is an activity related to
detecting, evaluating, understanding, and preventing adverse drug reactions
(ADR)<bold>1</bold>. Pharmacovigilance activities include periodic security update reports,
commonly called spontaneous reporting. Spontaneous reporting of adverse events
(AE)/ADR is one element of pharmacovigilance activities that help overcome
safety concerns after drug administration<bold>2</bold>. This reporting activity provides actual information regarding the safety
profile of real-life clinical practices compared to the results of clinical
trials using only a few samples and the safety of drugs studied in a limited
time<bold>3</bold>. Spontaneous reporting is a cost-effective, flexible, and highly effective
method of gathering information because health workers voluntarily submit
AE/ADR case reports to the National Pharmacovigilance Center of the Food and
Drug, The Indonesian Food and Drug Authority (Badan Pengawas Obat dan
Makanan Republik Indonesia, BPOM RI) for
analysis, which will later help to reduce the potential for AE/ADR in patients<bold>4</bold>.</p><p >Spontaneous
reporting is a method that contributes significantly to the improvement of
pharmacovigilance in some countries<bold>5</bold>. Several regulators in other countries have designed easy systems for
spontaneous reporting intending to increase the participation of health workers
in spontaneous reporting, but in reality, the rate of spontaneous AE/ADR
reporting is still low<bold>6</bold><bold>,</bold><bold>7</bold>. Spontaneous reporting of AE/ADR in several less progressive countries is
of particular concern, considering that these less developed countries
contribute to 80% of the disease burden in the world. However, they only
participate in AE/ADR reports in less than 1% of all global reports
(11,824,804)<bold>8</bold>.</p><p >Little
participation in AE/ADR reporting in less developed countries such as Indonesia
cannot be explained because the law does not require it. Spontaneous reporting
of AE/ADR, reporting still needs to be improved<bold>9</bold>. The low level of AE/ADR reporting is caused by several factors, such as not
caring about patient safety, feeling they have no responsibility to report,
complicated reporting procedures, and poor knowledge and attitudes of health
workers, which impacts AE/ADR reporting practices<bold>10</bold>. However, research on factors that correlate with spontaneous reporting
practices in Indonesia still needs to be improved. </p><p >Therefore,
research related to this needs to be done. Because research related to the
factors that influence the practice of spontaneous reporting is still new, it
requires instruments with good validity and reliability so that the data
collection process is accurate and precise. Research instruments for
observational research that look at the factors that influence a person
generally use questionnaires because questionnaires are relatively easy to
collect data in research and policy evaluation. Information containing
knowledge, attitudes, opinions, behavior, and facts will be easily collected
using a questionnaire<bold>11</bold>. Of course, a questionnaire with good validity and reliability requires a
development process first from evaluating the validity and reliability of test
results<bold>12</bold>.</p><p >Validity and
reliability are the two most essential and fundamental features in evaluating
any measurement instrument or tool for good research, one of which is a questionnaire.
Without assessing the reliability and validity of the study, it will be
difficult to describe the effects of measurement errors on the theoretical
relationships being measured<bold>13</bold>. Research with a valid questionnaire will produce data that follows the
construct built by the researcher. As for reliability, it serves to minimize
measurement errors from questionnaires when taking data. Reliability is an
indicator of questionnaire consistency when measuring certain concepts<bold>12</bold>. </p><p >Given the
importance of validity and reliability testing for a research questionnaire, it
should be a priority before taking data. However, a review of articles from 748
studies found that one-third did not attach procedures to establish validity
(31%) or reliability (33%). Meanwhile, developing accurate and precise
questionnaires is needed to decrease measurement errors, namely mismatches
between respondent attributes and survey responses<bold>14</bold>. Validity and reliability tests must be carried out before data collection
to reduce measurement errors and measure the questionnaire's reproducibility,
and the results will be evaluated later. Therefore, this study aims to test the
validity and reliability of a questionnaire developed to measure pharmacists'
knowledge and management of spontaneous reporting.</p>
			</sec><sec>
			<title>MATERIALS AND METHODS</title>
				<p ><bold>Materials</bold></p><p >The instrument in
this study was a questionnaire created by researchers based on World Health
Organization (WHO) and BPOM RI pharmacovigilance guidelines<bold>15</bold><bold>-</bold><bold>20</bold>. In addition, the
results of expert consultation were considered. The questionnaire consisted of
five parts: pharmacist demographic characteristics, knowledge included in
individual variables, psychological variables, environmental variables, and the
practices that pharmacists engaged in spontaneous reporting. For the
demographics section, there were 15 question items. For the part of knowledge
included in individual variables, there were 13 questions. For psychological
variables, there were 14 questions. Environmental variables totaled nine
questions, and practice summed 19 questions. The total number of questions in
the questionnaire was 55 questions (<bold>Table I</bold>). The questionnaire was validated
in two stages: the first stage was face validation for the overall appearance
of the questionnaire, and the second stage was construct validation to see
whether the questionnaire could produce data following the construct developed
by the researcher. Constructing validation in this questionnaire was divided
into two methods. The first method was biserial point correlation for the
knowledge section because the answer scale was the Guttman scale or dichotomy<bold>21</bold>. Because the answer
scale used an ordinal scale, the factor analysis method was applied for
psychological, environmental, and practice factors<bold>22</bold>.</p><p ><bold>Tab</bold><bold>le</bold><bold>I</bold><bold>.</bold> Question items in each instrument domain.</p><table-wrap><label>Table</label><table>
 <tr>
  <td>
  Variable
  </td>
  
  <td>
  Questions
  </td>
  
  <td>
  Number in questionnaire
  </td>
  
 </tr>
 <tr>
  <td>
  Knowledge
  </td>
  
  <td>
  One of the points in
  pharmacovigilance activities is the detection and prevention of AE/ADR so
  that additional reactions that are detrimental to the patient do not occur.
  </td>
  
  <td>
  1
  </td>
  
 </tr>
 <tr>
  
  <td>
  Adverse drug reaction monitoring
  applies to drugs that have been around for a long time, such as captopril,
  simvastatin, and the like
  </td>
  
  <td>
  2
  </td>
  
 </tr>
 <tr>
  
  <td>
  Drug reconstitution that is carried
  out haphazardly and without sterility has the potential to cause adverse
  events (AE) in patients.
  </td>
  
  <td>
  3
  </td>
  
 </tr>
 <tr>
  
  <td>
  Adverse Drug Reactions (ADR) are part
  of adverse events whose causes are known from the drugs consumed by the
  patient.
  </td>
  
  <td>
  4
  </td>
  
 </tr>
 <tr>
  
  <td>
  As health workers, pharmacists should
  report any AE/ADR encountered as part of their professional responsibility.
  </td>
  
  <td>
  5
  </td>
  
 </tr>
 <tr>
  
  <td>
  The spontaneous reporting of AE/ADR
  can only be done manually via a yellow form sent by post to the
  pharmacovigilance centre of Balai POM.
  </td>
  
  <td>
  6
  </td>
  
 </tr>
 <tr>
  
  <td>
  Post-Immunization Adverse Events
  during vaccine use are not required to be reported to BPOM.
  </td>
  
  <td>
  7
  </td>
  
 </tr>
 <tr>
  
  <td>
  The institution that acts as the
  national pharmacovigilance centre in Indonesia is BPOM.
  </td>
  
  <td>
  8
  </td>
  
 </tr>
 <tr>
  
  <td>
  Spontaneous reporting is only those
  that are unexpected (Unexpected Adverse Reaction).
  </td>
  
  <td>
  9
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR is one of the contributors to
  the highest number of deaths in various countries.
  </td>
  
  <td>
  10
  </td>
  
 </tr>
 <tr>
  
  <td>
  Decreased absorption of omeprazole
  due to drug interactions with antacids does not need to be reported.
  </td>
  
  <td>
  11
  </td>
  
 </tr>
 <tr>
  
  <td>
  Incidents of side effects due to drug
  overdose or medication errors need to be reported.
  </td>
  
  <td>
  12
  </td>
  
 </tr>
 <tr>
  
  <td>
  The withdrawal of the Albothyl
  product in 2018 and the call to improve the drug's indications so that it is
  not used for mouth ulcers is an example of implementing pharmacovigilance
  activities so that the public can avoid serious drug side effects.
  </td>
  
  <td>
  13
  </td>
  
 </tr>
 <tr>
  <td>
  Psychological
  </td>
  
  <td>
  Pharmacists in healthcare facilities
  play an essential role in pharmacovigilance activities.
  </td>
  
  <td>
  14
  </td>
  
 </tr>
 <tr>
  
  <td>
  Pharmacists in health service
  facilities must regularly update their knowledge regarding pharmacovigilance.
  </td>
  
  <td>
  15
  </td>
  
 </tr>
 <tr>
  
  <td>
  If a drug side effect occurs in their
  practice, the pharmacist is not obliged to report it.
  </td>
  
  <td>
  16
  </td>
  
 </tr>
 <tr>
  
  <td>
  Pharmacists in health service
  facilities are the public's first reference in reporting AE/ADR.
  </td>
  
  <td>
  17
  </td>
  
 </tr>
 <tr>
  
  <td>
  Pharmacists must receive special
  training regarding pharmacovigilance.
  </td>
  
  <td>
  18
  </td>
  
 </tr>
 <tr>
  
  <td>
  Spontaneous reporting of AE/ADR must
  be done voluntarily or as part of professionalism.
  </td>
  
  <td>
  19
  </td>
  
 </tr>
 <tr>
  
  <td>
  Reporting and monitoring of AE/ADR
  will be beneficial for patients.
  </td>
  
  <td>
  20
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR that occur due to
  over-the-counter drugs/limited over-the-counter and over-the-counter drugs
  must also be reported.
  </td>
  
  <td>
  21
  </td>
  
 </tr>
 <tr>
  
  <td>
  Reporting AE/ADR will add more
  insight regarding the side effects of drugs encountered in practice.
  </td>
  
  <td>
  22
  </td>
  
 </tr>
 <tr>
  
  <td>
  Reporting AE/ADR experienced by
  patients is a sign that their concerns are being taken seriously.
  </td>
  
  <td>
  23
  </td>
  
 </tr>
 <tr>
  
  <td>
  Spontaneous reporting of AE/ADR is
  part of pharmaceutical care.
  </td>
  
  <td>
  24
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR must be reported even if the
  impact does not result in hospitalization, life-threatening conditions,
  disability, or death.
  </td>
  
  <td>
  25
  </td>
  
 </tr>
 <tr>
  
  <td>
  All adverse events/ESOs that occur as
  a result of drugs that have just received distribution permits and medicines
  that have been on the market for a long time must be reported.
  </td>
  
  <td>
  26
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR reporting must be done
  immediately, especially for dangerous or unexpected events (Unexpected
  Adverse Reaction).
  </td>
  
  <td>
  27
  </td>
  
 </tr>
 <tr>
  <td>
  Environment
  </td>
  
  <td>
  The pharmacist where I practice
  applies a regular shift work system.
  </td>
  
  <td>
  28
  </td>
  
 </tr>
 <tr>
  
  <td>
  In one work shift, the pharmacist at
  my workplace practices according to the specified working hours.
  </td>
  
  <td>
  29
  </td>
  
 </tr>
 <tr>
  
  <td>
  The pharmacists' working hours where
  I work follow the given workload.
  </td>
  
  <td>
  30
  </td>
  
 </tr>
 <tr>
  
  <td>
  My workplace will give rewards/awards
  to pharmacists if they make innovations in their work or succeed in achieving
  specific targets.
  </td>
  
  <td>
  31
  </td>
  
 </tr>
 <tr>
  
  <td>
  Promotions at my workplace are
  carried out objectively based on the achievements and contributions of a
  pharmacist.
  </td>
  
  <td>
  32
  </td>
  
 </tr>
 <tr>
  
  <td>
  The income I get from my workplace is
  enough for me because it matches my workload.
  </td>
  
  <td>
  33
  </td>
  
 </tr>
 <tr>
  
  <td>
  My workplace will provide additional
  income if there is extra work or overtime provided
  </td>
  
  <td>
  34
  </td>
  
 </tr>
 <tr>
  
  <td>
  The portion of work at my workplace
  is proportional enough to do other work without needing overtime.
  </td>
  
  <td>
  35
  </td>
  
 </tr>
 <tr>
  
  <td>
  I complete work while at work and
  never do work at home/outside of my working hours
  </td>
  
  <td>
  36
  </td>
  
 </tr>
 <tr>
  <td>
  Practice
  </td>
  
  <td>
  The frequency with which I encounter
  reports of drug side effects or adverse events from patients at work.
  </td>
  
  <td>
  37
  </td>
  
 </tr>
 <tr>
  
  <td>
  The frequency with which the hospital
  where I work reports drug side effects or adverse events to the BPOM National
  Pharmacovigilance Center
  </td>
  
  <td>
  38
  </td>
  
 </tr>
 <tr>
  
  <td>
  I immediately report all drug side
  effects or adverse events reported by the patient to the unit head/head of
  pharmacy installation/pharmacist responsible for spontaneous reporting to
  BPOM.
  </td>
  
  <td>
  39
  </td>
  
 </tr>
 <tr>
  
  <td>
  I document all reports of drug side
  effects or adverse events from patients, both unexpected and expected.
  </td>
  
  <td>
  40
  </td>
  
 </tr>
 <tr>
  
  <td>
  I report and document all actions and
  interventions I provide to patients according to the patient's complaints.
  </td>
  
  <td>
  41
  </td>
  
 </tr>
 <tr>
  
  <td>
  Suppose there is a complaint that a
  patient has a dry cough due to using the drug captopril. In that case, I will
  report it to the unit head/head of pharmacy installation/pharmacist
  responsible for spontaneous reporting to BPOM.
  </td>
  
  <td>
  42
  </td>
  
 </tr>
 <tr>
  
  <td>
  Suppose there is a complaint that a
  patient experiences extrapyramidal syndrome due to the use of the drug
  metoclopramide. In that case, I will report it to the unit head/head of
  pharmacy installation/pharmacist responsible for spontaneous reporting to
  BPOM.
  </td>
  
  <td>
  43
  </td>
  
 </tr>
 <tr>
  
  <td>
  Suppose there is an incident of decreased
  absorption of the drug omeprazole as a result of drug interactions with
  antacids. In that case, I will report it to the unit head/head of pharmacy
  installation/pharmacist responsible for spontaneous reporting to BPOM.
  </td>
  
  <td>
  44
  </td>
  
 </tr>
 <tr>
  
  <td>
  I carried out a causality analysis
  first with the doctor who provided therapy to the patient to ensure the
  causality of the side effects of the medication experienced by the patient.
  </td>
  
  <td>
  45
  </td>
  
 </tr>
 <tr>
  
  <td>
  I include information in the form of
  reporting data, data on patients who submit complaints, complaints felt by
  patients, and data on suspected drugs in every report I submit to the head of
  the unit/head of the pharmacy installation/pharmacist responsible for
  spontaneous reporting to BPOM.
  </td>
  
  <td>
  46
  </td>
  
 </tr>
 <tr>
  
  <td>
  I discussed with the doctor who
  provides therapy to treat patients who experience side effects from drugs.
  </td>
  
  <td>
  47
  </td>
  
 </tr>
 <tr>
  
  <td>
  I take my time at work to handle drug
  safety incident complaints from patients immediately.
  </td>
  
  <td>
  48
  </td>
  
 </tr>
 <tr>
  
  <td>
  I take the time to do documentation
  and report cases of drug side effects or adverse events encountered in
  patients.
  </td>
  
  <td>
  49
  </td>
  
 </tr>
 <tr>
  
  <td>
  I prioritize work related to patient
  safety while undergoing therapy.
  </td>
  
  <td>
  50
  </td>
  
 </tr>
 <tr>
  
  <td>
  I apply all points of clinical
  pharmacy services, including monitoring drug side effects (MESO) following
  the Minister of Health Regulations, where I practice.
  </td>
  
  <td>
  51
  </td>
  
 </tr>
 <tr>
  
  <td>
  I actively participate in the
  spontaneous reporting of drug side effects or adverse events as a form of
  professionalism and compliance with regulations.
  </td>
  
  <td>
  52
  </td>
  
 </tr>
 <tr>
  
  <td>
  I have a spontaneous reporting
  account at e-meso.pom.go.id or the e-meso mobile smartphone application and
  operate it actively.
  </td>
  
  <td>
  53
  </td>
  
 </tr>
 <tr>
  
  <td>
  I provide a yellow form for
  spontaneous reporting of drug side effects to BPOM manually at my practice.
  </td>
  
  <td>
  54
  </td>
  
 </tr>
 <tr>
  
  <td>
  I participated in multilevel
  pharmacovigilance training held by BPOM as the national pharmacovigilance
  centre.
  </td>
  
  <td>
  55
  </td>
  
 </tr>
</table></table-wrap><p ><bold>Methods</bold></p><p >Design and
participant</p><p >This
study was conducted between September and October 2023 in pharmacists working
full-time at type C hospitals in Surabaya and Sidoarjo, East Java, Indonesia.
Type C hospitals were chosen because the number of type C hospitals is the
largest in Indonesia, but the contribution of reports of adverse drug reactions
is low<bold>16</bold><bold>,</bold><bold>23</bold>. There were 30
samples recommended by Hertzog<bold>24</bold>. The Health
Research Ethics Commission (KEPK), Faculty of Dentistry, Universitas Airlangga,
issued the certificate of ethical eligibility for this study, with number
987/HRECC. FODM/VIII/2023.</p><p >Face validity</p><p >The method used to
assess face validity was to provide a suggestion and improvement column at the
end of the questionnaire to comment on all parts of the questionnaire in terms
of language, font size, font, and word choice. Face validity was a subjective
assessment of the operation of a construct. A test was valid if its content seemed
relevant to the person working on it. It evaluated the appearance of the
questionnaire in terms of feasibility, readability, consistency of style and
format, and clarity of the language used. In other words, face validity
referred to the researcher's subjective assessment of the presentation and
relevance of the measuring instrument, whether the items appeared relevant,
reasonable, clear, and transparent<bold>25</bold>.</p><p ><bold>Data analysis</bold></p><p >Construct validity
test</p><p >The construct
validity test used two methods to determine the questionnaire's construct
conformity. The first method used the biserial point correlation for the
knowledge section, and the second used factor analysis for psychological,
environmental, and practice variables questionnaires. For biserial point
correlation to check the validity of the knowledge section, the method using
Microsoft Excel tools to show the difference between the r-value and the
r-table, in which Rpb was biserial point correlation coefficient, xi was
average total score of respondents who answered correctly, xt was average total
score of all respondents, Pi was proportion of correct answers item i, Qi was
1-Pi, and St was standard deviation of the total score, as shown in <bold>Equation 1</bold>.<bold>Equation 1</bold> was used to
calculate the r-value to show the validity of the questionnaire item<bold>26</bold>. This calculation
was applied to each knowledge question item. The question item was considered
valid if the computed r-value offered a value greater than the r-table, and
vice versa.</p><p >
 
 
  
  
  
  
  
  
  
  
  
  
  
  
 
 
 

 
  [1]</p><p >The
second method was factor analysis using several indicators using IBM SPSS
Statistics 26 (https://www.ibm.com/support/pages/downloading-ibm-spss-statistics-26). The first
indicator was the Kaiser-Meyer-Olkin (KMO) measurement. This parameter compared
the correlation coefficient value with the partial coefficient value. The
requirement for factor analysis was that the KMO value had to be higher than
0.5. Bartlett's Test of sphericity tested the dependence between the variables
being tested. This parameter helped indicate the absence of correlation between
variables with each other in the community. The significance value in
Bartlett's Test had to be less than 0.05 so that the process could continue for
factor analysis. The following indicator showed the result of the calculation
of the anti-image correlation. Grades with 'A' indicated the Measure of
Sampling Adequacy (MSA) value. If the MSA number for a variable was below 0.5,
then the variable had to be excluded, and variable selection had to be
repeated. The last indicators were the Component Matrix and Rotated Component
Matrix, which helped explain the spread of variables into factors formed. The
Component Matrix confirmed whether or not there was a correlation between items
and components. A high correlation value showed a solid relationship between
the items and the components so that the items could be used as a factor. In a
complex matrix, interpreting these factors was quite rare because it was
difficult. Therefore, the factor alteration used in matrix factor rotation was
converted into a more friendly form to understand. The steps for factor
analysis in SPSS were selecting the analysis menu, selecting dimension and
factor reduction, selecting the variables to be analyzed, selecting the
descriptive option, checking the initial solution, KMO, Bartlett's Test of
sphericity, and anti-image, selecting OK, then selecting the rotation menu to
select varimax and check rotated solution and loading plots, and finally
selecting OK for the analysis process<bold>27</bold>.</p><p >Reliability test</p><p >Reliability testing
aimed to see how consistent a questionnaire was when used for data collection.
The method used was to look at the value of Cronbach α, which had to be greater
than 0.6 for qualified reliability<bold>28</bold>. However, another
theory was that if the Cronbach α value was 0.5-0.7, the questionnaire could be
considered moderately reliable and still be used for research data collection<bold>29</bold><bold>,</bold><bold>30</bold>. The way to carry
out reliability analysis in IBM SPSS Statistics 26 tools was to select the
analyze menu, click scale and select reliability analysis, then choose the
variable to be measured, click the statistics menu, and check the scale if the
item deleted option, then clicked ok to process the analysis, later the results
would display the Cronbach α value of analyzed variables.</p>
			</sec><sec>
			<title>RESULTS AND DISCUSSION</title>
				<p >This questionnaire
pilot test found 30 pharmacist respondents who worked in type C hospitals in
Surabaya and Sidoarjo. The majority of respondents were 28 (93.3%) female. Most
respondents were 28 (93.3%) from type C hospitals in Surabaya and 2 (6.6%) from
type C hospitals in Sidoarjo. Face validity shows that overall, the pilot test
respondents said that the grammar of the questionnaire was excellent and easy
to understand, and the sentence structure was not ambiguous so that respondents
could understand the meaning of the questions on the questionnaire. The font
size and typeface used are also ideal, according to respondents. The form validation
method is similar to testing the validity of questionnaires conducted in India
when testing the validity of work-related stress questionnaires (TAWS-16)<bold>31</bold>.</p>

<p >The results of construct
validation of the knowledge question item section that is included in
individual variables can be seen in <bold>Table II</bold>. The calculation results in <bold>Table II</bold> are interpreted by
comparing the calculated r-value with the r-table. The question item is
arguably valid if the calculated r-value exceeds the r-table<bold>32</bold>. Based on the data
above, two knowledge question items show invalid results because the calculated
r-value is smaller than the r-table: question items number 4 and 13. Several
factors can cause the invalidity of the question item. The first possibility is
that the question item contains a sentence that leads the respondent to lean
toward one answer choice, or the other option is that the question item cannot
describe the intention the researcher wants to ask. Hence, the respondent gives
an inappropriate response<bold>33</bold>.</p>



<p ><bold>Tab</bold><bold>le</bold><bold>II</bold><bold>.</bold> Knowledge question item validation results.</p>



<table-wrap><label>Table</label><table>
 <tr>
  <td>
  Number
  </td>
  
  <td>
  R table
  </td>
  
  <td>
  R-value
  </td>
  
  <td>
  Interpretation
  of results
  </td>
  
  <td>
  Number in
  Questionnaire
  </td>
  
 </tr>
 <tr>
  <td>
  1
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.559027
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  1
  </td>
  
 </tr>
 <tr>
  <td>
  2
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.374257
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  2
  </td>
  
 </tr>
 <tr>
  <td>
  3
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.455515
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  3
  </td>
  
 </tr>
 <tr>
  <td>
  4
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  -0.2747*
  </td>
  
  <td>
  Item not valid
  </td>
  
  <td>
  4
  </td>
  
 </tr>
 <tr>
  <td>
  5
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.403602
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  5
  </td>
  
 </tr>
 <tr>
  <td>
  6
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.488807
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  6
  </td>
  
 </tr>
 <tr>
  <td>
  7
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.52928
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  7
  </td>
  
 </tr>
 <tr>
  <td>
  8
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.421993
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  8
  </td>
  
 </tr>
 <tr>
  <td>
  9
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.548176
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  9
  </td>
  
 </tr>
 <tr>
  <td>
  10
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.471245
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  10
  </td>
  
 </tr>
 <tr>
  <td>
  11
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.397606
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  11
  </td>
  
 </tr>
 <tr>
  <td>
  12
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.569651
  </td>
  
  <td>
  Item valid
  </td>
  
  <td>
  12
  </td>
  
 </tr>
 <tr>
  <td>
  13
  </td>
  
  <td>
  0.361
  </td>
  
  <td>
  0.268317*
  </td>
  
  <td>
  Item not valid
  </td>
  
  <td>
  13
  </td>
  
 </tr>
</table></table-wrap>



<p >* invalid item</p>





<p >The next validity
test is for psychological, environmental, and practical variables, using factor
analysis methods. The first indicator shows the value of the KMO Measure and
the significance values of psychological, environmental, and practice
variables. The KMO and Bartlett's tests are data suitability tests that must be
performed before interpreting the factor analysis results. The MSA is a
statistical value that indicates the proportion of diversity in the variables
on which factor analysis is based<bold>34</bold>. If the MSA value
&gt;0.50, It is concluded that the questionnaire can be used to measure
respondents' answers precisely. If it shows a KMO value of more than 0.5 and a
significance value of less than 0.05, the variable can be used for further data
collection and analysis<bold>27</bold>.</p>

<p >Bartlett's test examines
whether the indicators used correlate and are suitable for factor analysis. If
the value of Bartlett's test is less than 0.05, it is concluded that the
indicators used are correlated and ideal for factor analysis. The KMO values of
psychological, environmental, and practice variables are 0.535 each, 0,582, and
0.634, with each significant value below 0.05. These results show that the
indicators used in this study are correlated and appropriate for factor
analysis<bold>27</bold>.</p>

<p >Factor analysis
requires the data matrix to correlate factor analysis. The correlation value is
shown in the anti-image correlation matrix. The MSA value on the diagonal
anti-image correlation with the sign is expected to be above 0.5<bold>27</bold>. <bold>Table III</bold>shows that each
variable has a question item whose value is less than 0.5. The first of the
psychological variables shows that items 4, 8, and 13 have values less than
0.5, which are 0.229, 0.386, and 0.306. The second environmental variable is
shown in item number 3; whose value is less than 0.5, which is 0.4<bold>35</bold>. Finally, from the
practice variables, there are four items whose value is less than 0.5: items 1,
13, 18, and 19. Based on these results, question items with an MSA value of
less than 0.5 cannot be continued for the data retrieval process, while other
items with an MSA value of more than 0.5 can be used for the data retrieval
process<bold>22</bold>.</p>

<p >The results of the
subsequent construct validation can be seen in <bold>Table IV</bold>. <bold>Table IV</bold> presents loading
factor coefficient data explaining the connection between the origin variable
and the factor. A significant correlation value denotes a solid relationship
between the factor and the original variable, which means that the variable can
be used as a factor. In a complex matrix, interpreting these factors is quite
rare because it is difficult. Therefore, the factor alteration used in matrix
factor rotation is converted into a more friendly form to understand<bold>36</bold>.</p>

<p >Rotated Component
Matrix is the value of the distribution of variables that have been extracted
into factors that are formed based on the loading factor after the transformation
process to a form that is easier to understand. The loading factor value could
turn after the process rotation. Component variables with a loading factor of
less than 0.5 are deemed not to contribute to the factors formed significantly,
so they must be eliminated from the factors formed<bold>27</bold>. However, for this
loading factor value, there is a theory that says if the value is more than
0.3, then the item has shown a close relationship between items on the factor
formed<bold>35</bold>. However, in this
study, all items on each variable have a loading factor value of more than 0.5,
meaning that all indicator items have a close relationship with the factors
formed<bold>36</bold>.</p>

<p ><bold>Tab</bold><bold>le</bold><bold>III</bold><bold>.</bold> Measurement results of MSA of
psychological, environment, and practice variables.</p>

<table-wrap><label>Table</label><table>
 <tr>
  
  <td>
  Anti-image correlation
  </td>
  
 </tr>
 <tr>
  <td>
  Number of items
  </td>
  <td>
  Standard
  </td>
  <td>
  MSA value
  </td>
 </tr>
 <tr>
  <td>
  Var. psychological
  </td>
  <td>
  Number in questionnaire
  </td>
  <td>
  Var. environment
  </td>
  <td>
  Number in questionnaire
  </td>
  <td>
  Var. practice
  </td>
  <td>
  Number in questionnaire
  </td>
 </tr>
 <tr>
  <td>
  1
  </td>
  <td>
  0.5
  </td>
  <td>
  0.724
  </td>
  <td>
  14
  </td>
  <td>
  0.628
  </td>
  <td>
  28
  </td>
  <td>
  0.494*
  </td>
  <td>
  37
  </td>
 </tr>
 <tr>
  <td>
  2
  </td>
  <td>
  0.5
  </td>
  <td>
  0.513
  </td>
  <td>
  15
  </td>
  <td>
  0.576
  </td>
  <td>
  29
  </td>
  <td>
  0.705
  </td>
  <td>
  38
  </td>
 </tr>
 <tr>
  <td>
  3
  </td>
  <td>
  0.5
  </td>
  <td>
  0.560
  </td>
  <td>
  16
  </td>
  <td>
  0.435*
  </td>
  <td>
  30
  </td>
  <td>
  0.719
  </td>
  <td>
  39
  </td>
 </tr>
 <tr>
  <td>
  4
  </td>
  <td>
  0.5
  </td>
  <td>
  0.229*
  </td>
  <td>
  17
  </td>
  <td>
  0.623
  </td>
  <td>
  31
  </td>
  <td>
  0.820
  </td>
  <td>
  40
  </td>
 </tr>
 <tr>
  <td>
  5
  </td>
  <td>
  0.5
  </td>
  <td>
  0.713
  </td>
  <td>
  18
  </td>
  <td>
  0.518
  </td>
  <td>
  32
  </td>
  <td>
  0.653
  </td>
  <td>
  41
  </td>
 </tr>
 <tr>
  <td>
  6
  </td>
  <td>
  0.5
  </td>
  <td>
  0.666
  </td>
  <td>
  19
  </td>
  <td>
  0.596
  </td>
  <td>
  33
  </td>
  <td>
  0.511
  </td>
  <td>
  42
  </td>
 </tr>
 <tr>
  <td>
  7
  </td>
  <td>
  0.5
  </td>
  <td>
  0.778
  </td>
  <td>
  20
  </td>
  <td>
  0.630
  </td>
  <td>
  34
  </td>
  <td>
  0.727
  </td>
  <td>
  43
  </td>
 </tr>
 <tr>
  <td>
  8
  </td>
  <td>
  0.5
  </td>
  <td>
  0.386*
  </td>
  <td>
  21
  </td>
  <td>
  0.616
  </td>
  <td>
  35
  </td>
  <td>
  0.525
  </td>
  <td>
  44
  </td>
 </tr>
 <tr>
  <td>
  9
  </td>
  <td>
  0.5
  </td>
  <td>
  0.529
  </td>
  <td>
  22
  </td>
  <td>
  0.547
  </td>
  <td>
  36
  </td>
  <td>
  0.544
  </td>
  <td>
  45
  </td>
 </tr>
 <tr>
  <td>
  10
  </td>
  <td>
  0.5
  </td>
  <td>
  0.517
  </td>
  <td>
  23
  </td>
  
  
  <td>
  0.719
  </td>
  <td>
  46
  </td>
 </tr>
 <tr>
  <td>
  11
  </td>
  <td>
  0.5
  </td>
  <td>
  0.555
  </td>
  <td>
  24
  </td>
  
  
  <td>
  0.651
  </td>
  <td>
  47
  </td>
 </tr>
 <tr>
  <td>
  12
  </td>
  <td>
  0.5
  </td>
  <td>
  0.777
  </td>
  <td>
  25
  </td>
  
  
  <td>
  0.705
  </td>
  <td>
  48
  </td>
 </tr>
 <tr>
  <td>
  13
  </td>
  <td>
  0.5
  </td>
  <td>
  0.306*
  </td>
  <td>
  26
  </td>
  
  
  <td>
  0.443*
  </td>
  <td>
  49
  </td>
 </tr>
 <tr>
  <td>
  14
  </td>
  <td>
  0.5
  </td>
  <td>
  0.541
  </td>
  <td>
  27
  </td>
  
  
  <td>
  0.620
  </td>
  <td>
  50
  </td>
 </tr>
 <tr>
  <td>
  15
  </td>
  <td>
  0.5
  </td>
  
  
  
  
  <td>
  0.628
  </td>
  <td>
  51
  </td>
 </tr>
 <tr>
  <td>
  16
  </td>
  <td>
  0.5
  </td>
  
  
  
  
  <td>
  0.675
  </td>
  <td>
  52
  </td>
 </tr>
 <tr>
  <td>
  17
  </td>
  <td>
  0.5
  </td>
  
  
  
  
  <td>
  0.667
  </td>
  <td>
  53
  </td>
 </tr>
 <tr>
  <td>
  18
  </td>
  <td>
  0.5
  </td>
  
  
  
  
  <td>
  0.161*
  </td>
  <td>
  54
  </td>
 </tr>
 <tr>
  <td>
  19
  </td>
  <td>
  0.5
  </td>
  
  
  
  
  <td>
  0.492*
  </td>
  <td>
  55
  </td>
 </tr>
</table></table-wrap>

<p >* item does not meet
the requirement</p>



<p ><bold>Tab</bold><bold>le</bold><bold>IV</bold><bold>.</bold> Results of loading factor measurement of psychological,
environmental, and practice variables from the Rotated Component Matrix.</p>

<table-wrap><label>Table</label><table>
 <tr>
  
  
  
  
  <td>
  Rotated
  Component Matrix
  </td>
  
  
  
 </tr>
 <tr>
  <td>
  Item number
  </td>
  
  <td>
  Var.
  psychological
  </td>
  
  <td>
  Var. environment
  </td>
  
  <td>
  Var. practice
  </td>
  
 </tr>
 <tr>
  
  <td>
  Loading factor
  value
  </td>
  
  <td>
  Factor
  categories
  </td>
  
  <td>
  Number in
  questionnaire
  </td>
  
  <td>
  Loading factor
  value
  </td>
  
  <td>
  Factor
  categories
  </td>
  
  <td>
  Number in
  questionnaire
  </td>
  
  <td>
  Loading factor
  value
  </td>
  
  <td>
  Factor categories
  </td>
  
  <td>
  Number in
  questionnaire
  </td>
  
 </tr>
 <tr>
  <td>
  1
  </td>
  
  <td>
  0.764
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  14
  </td>
  
  <td>
  0.775
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  28
  </td>
  
  <td>
  0.698
  </td>
  
  <td>
  Factor 5
  </td>
  
  <td>
  37
  </td>
  
 </tr>
 <tr>
  <td>
  2
  </td>
  
  <td>
  0.681
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  15
  </td>
  
  <td>
  0.890
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  29
  </td>
  
  <td>
  0.728
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  38
  </td>
  
 </tr>
 <tr>
  <td>
  3
  </td>
  
  <td>
  0.798
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  16
  </td>
  
  <td>
  0.890
  </td>
  
  <td>
  Factor 4*
  </td>
  
  <td>
  30
  </td>
  
  <td>
  0.849
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  39
  </td>
  
 </tr>
 <tr>
  <td>
  4
  </td>
  
  <td>
  0.889
  </td>
  
  <td>
  Factor 4
  </td>
  
  <td>
  17
  </td>
  
  <td>
  0.660
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  31
  </td>
  
  <td>
  0.905
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  40
  </td>
  
 </tr>
 <tr>
  <td>
  5
  </td>
  
  <td>
  0.641
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  18
  </td>
  
  <td>
  0.829
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  32
  </td>
  
  <td>
  0.572
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  41
  </td>
  
 </tr>
 <tr>
  <td>
  6
  </td>
  
  <td>
  0.602
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  19
  </td>
  
  <td>
  0.853
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  33
  </td>
  
  <td>
  0.821
  </td>
  
  <td>
  Factor 4*
  </td>
  
  <td>
  42
  </td>
  
 </tr>
 <tr>
  <td>
  7
  </td>
  
  <td>
  0.759
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  20
  </td>
  
  <td>
  0.804
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  34
  </td>
  
  <td>
  0.745
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  43
  </td>
  
 </tr>
 <tr>
  <td>
  8
  </td>
  
  <td>
  0.599
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  21
  </td>
  
  <td>
  0.780
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  35
  </td>
  
  <td>
  0.597
  </td>
  
  <td>
  Factor 6*
  </td>
  
  <td>
  44
  </td>
  
 </tr>
 <tr>
  <td>
  9
  </td>
  
  <td>
  0.805
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  22
  </td>
  
  <td>
  0.530
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  36
  </td>
  
  <td>
  0.682
  </td>
  
  <td>
  Factor 5
  </td>
  
  <td>
  45
  </td>
  
 </tr>
 <tr>
  <td>
  10
  </td>
  
  <td>
  0.757
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  23
  </td>
  
  
  
  
  
  
  
  <td>
  0.867
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  46
  </td>
  
 </tr>
 <tr>
  <td>
  11
  </td>
  
  <td>
  0.799
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  24
  </td>
  
  
  
  
  
  
  
  <td>
  0.724
  </td>
  
  <td>
  Factor 2*
  </td>
  
  <td>
  47
  </td>
  
 </tr>
 <tr>
  <td>
  12
  </td>
  
  <td>
  0.777
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  25
  </td>
  
  
  
  
  
  
  
  <td>
  0.733
  </td>
  
  <td>
  Factor 2*
  </td>
  
  <td>
  48
  </td>
  
 </tr>
 <tr>
  <td>
  13
  </td>
  
  <td>
  0.832
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  26
  </td>
  
  
  
  
  
  
  
  <td>
  0.918
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  49
  </td>
  
 </tr>
 <tr>
  <td>
  14
  </td>
  
  <td>
  0.639
  </td>
  
  <td>
  Factor 2
  </td>
  
  <td>
  27
  </td>
  
  
  
  
  
  
  
  <td>
  0.689
  </td>
  
  <td>
  Factor 3*
  </td>
  
  <td>
  50
  </td>
  
 </tr>
 <tr>
  <td>
  15
  </td>
  
  
  
  
  
  
  
  
  
  
  
  
  
  <td>
  0.687
  </td>
  
  <td>
  Factor 2*
  </td>
  
  <td>
  51
  </td>
  
 </tr>
 <tr>
  <td>
  16
  </td>
  
  
  
  
  
  
  
  
  
  
  
  
  
  <td>
  0.560
  </td>
  
  <td>
  Factor 1
  </td>
  
  <td>
  52
  </td>
  
 </tr>
 <tr>
  <td>
  17
  </td>
  
  
  
  
  
  
  
  
  
  
  
  
  
  <td>
  0.663
  </td>
  
  <td>
  Factor 2*
  </td>
  
  <td>
  53
  </td>
  
 </tr>
 <tr>
  <td>
  18
  </td>
  
  
  
  
  
  
  
  
  
  
  
  
  
  <td>
  0.907
  </td>
  
  <td>
  Factor 6*
  </td>
  
  <td>
  54
  </td>
  
 </tr>
 <tr>
  <td>
  19
  </td>
  
  
  
  
  
  
  
  
  
  
  
  
  
  <td>
  0.849
  </td>
  
  <td>
  Factor 4*
  </td>
  
  <td>
  55
  </td>
  
 </tr>
</table></table-wrap>

<p >* item does not meet
the requirement</p>





<p >The calculated
component transformation analysis results must support the results in <bold>Table IV</bold>. Suppose the
component value of a variable shows a value that is large or more than 0.5. In
that case, the relationship between the factors or components that make up a
variable is getting closer<bold>37</bold>. Based on the
component transformation matrix calculation, psychological variables are
divided into four components. Still, component number three has a value of less
than 0.5, so component number three is considered not to describe the construct
of psychological variables. In <bold>Table IV</bold>, the psychological variables
section results from factor loadings on psychological variables, which are
included in factor or component 3 in items 8, 12, and 13, which are not
included as components that make up psychological variables. Likewise, for
environmental variables where the results of the transformation component
matrix are only components 1 and 2, which have a solid correlation, meaning
that the environmental variable question items included in components 3 and 4
are considered weak variable constituents, therefore environmental variable
question items number 3, 6, and 8 are deemed unable to represent environmental
variables. In the last part, based on the results of the component
transformation matrix, the training variables show that only components 1 and 5
have a strong correlation, meaning that the training questions included in
components 2, 3, 4, and 6 cannot represent the training variables.</p>

<p >The reliability test
aims to see how consistent a questionnaire item is when tested on several
research samples. The reliability value is potentially high if each item has a
close correlation<bold>38</bold>. The Cronbach α
value must be greater than 0.6 to be eligible for reliability<bold>28</bold>. Nevertheless,
another theory<bold>39</bold> says that if the
value of Cronbach α is 0.4 to 0.6, it can be reliable, calculated, and used for
data collection. The reliability test results in <bold>Table V</bold> show that the
Cronbach α value of all variables is classified as reliable because the value
is more than 0.6, meaning that question items from psychological,
environmental, and practice variables are reproducible and worthy of being used
as research instruments<bold>28</bold>. However, the
corrected item's total correlation value is another parameter to see a question
item's reliability.</p>



<p ><bold>Tab</bold><bold>le</bold><bold>V</bold><bold>.</bold> Cronbach α value of psychological, environmental, and practice variables.</p>

<table-wrap><label>Table</label><table>
 <tr>
  <td>
  Cronbach α value
  </td>
  
 </tr>
 <tr>
  <td>
  Var.
  psychological
  </td>
  
  <td>
  Var. environment
  </td>
  
  <td>
  Var. practice
  </td>
  
 </tr>
 <tr>
  <td>
  0.865
  </td>
  
  <td>
  0.636
  </td>
  
  <td>
  0.850
  </td>
  
 </tr>
</table></table-wrap>





<p >The function of the
corrected item-total correlation value is to select items whose measuring
function is under the test measuring function as the compiler desires. In other
words, it is to choose an item that measures the same thing as what the test as
a whole measure<bold>40</bold>. According to Azwar<bold>41</bold>, a coefficient
limit of &gt;0.30 is commonly employed as a criterion for selecting items based
on item-total correlation. As part of the test, all items with a correlation
coefficient of at least 0.30 were certified psychometrically eligible. However,
another theory<bold>42</bold> says that the
item-total correlation value must be greater than the r-table to be reliable.
After analysis, results show unqualified values based on the two theories
above; in psychological variables, item 4 shows values less than 0.3 and more
minor than the r-table. For environment variables, items 2, 3, 5, and 9
indicate low values, then practice items 6, 18, and 19, whose values do not
qualify. Therefore, some of these items can be removed from the questionnaire. </p>

<p >The results of this
validity and reliability test aim to select question items suitable for use in
the data collection process because they relate to the purpose of the
questionnaire, which is to get answers under the construct built into the
questionnaire. Regarding the validity and reliability test results, there is a
theory that states that every valid questionnaire question item must also have
good reliability because if the item is accurate, then the reproducibility is
also good. Unlike reliability, not all questionnaires with good reliability
will result in valid question items because the accuracy of the answers has not
been tested<bold>43</bold>.</p>

<p >Based on the
validity and reliability test results, several question items must be
eliminated because they cannot provide accurate answers according to the
variable construct created. The final form of the questionnaire, which has been
evaluated for validity and reliability, can be seen in <bold>Table VI</bold>. From the 55
initial question items, the number was reduced to only 34, and this was because
21 question items in the questionnaire did not meet the validity and
reliability requirements.</p>

<p >This research has
limitations, and the sample size is only 30 respondents because few pharmacists
in type C hospitals are willing to be pilot test respondents. This small number
of respondents causes a lack of representation, potentially affecting the
results' validity and reliability<bold>44</bold>. However, on the
other hand, this research has strength. The strength of this research is that
there are no open questions in the questionnaire developed, so the respondents'
answers are common to process. Apart from that, the analysis used to test the
construct validity of the questionnaire is relatively common because most
questions use an ordinal answer scale, so the researcher can use the factor
analysis method to construct validity.</p>

<p >Regardless of the
strengths and limitations above, this questionnaire benefits researchers in
finding out the factors that influence spontaneous reporting practices by
pharmacists because this questionnaire can provide accurate, precise, and
reproducible results. This questionnaire can be used for pharmacist respondents
who work in type C hospitals in East Java. Suppose this questionnaire will be
used for pharmacists in other types of hospitals or health services, such as
community health centers or drug stores, or for pharmacists outside East Java.
This questionnaire can be used but requires a verification process to adapt it
to the pharmacist's workplace and location. Suggestions for the next step when
developing a research questionnaire instrument: the researcher must start with
making the correct conceptual framework design, compiling the questions that
the researcher wants to make in the questionnaire, and determining what type of
question-answer it looks like, then make a filter that suits the target
respondent, then eliminate various potential biases and double questions in one
question item. Then, it also made a picture of what the analysis will be like
and the last and main one that pilots must test before being used for research<bold>45</bold>.</p>



<p ><bold>Tab</bold><bold>le</bold><bold>VI</bold><bold>.</bold> Question items in each instrument domain after evaluation
of validity and reliability results.</p>

<table-wrap><label>Table</label><table>
 <tr>
  <td>
  Variable
  </td>
  
  <td>
  Questions
  </td>
  
  <td>
  Number in questionnaire
  </td>
  
  <td>
  Explanation
  </td>
  
 </tr>
 <tr>
  <td>
  Knowledge
  </td>
  
  <td>
  One of the points in
  pharmacovigilance activities is the detection and prevention of AE/ADR so
  that additional reactions that are detrimental to the patient do not occur.
  </td>
  
  <td>
  1
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Adverse drug reaction monitoring
  applies to drugs that have been around for a long time, such as captopril,
  simvastatin, and the like
  </td>
  
  <td>
  2
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Adverse events (AE) can occur in
  patients if medication reconstitution is done hastily and without an aseptic
  technique.
  </td>
  
  <td>
  3
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Adverse Drug Reactions (ADR) are part
  of adverse events whose causes are known from the drugs consumed by the
  patient.
  </td>
  
  <td>
  4
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  As health workers, pharmacists should
  report any AE/ADR encountered as part of their professional responsibility.
  </td>
  
  <td>
  5
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  The spontaneous reporting of AE/ADR
  can only be done manually via a yellow form mailed to the Balai POM
  pharmacovigilance centre.
  </td>
  
  <td>
  6
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Post-Immunization Adverse events
  occurring during vaccine administration are not required to be reported to
  BPOM.
  </td>
  
  <td>
  7
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  The institution that acts as the
  national pharmacovigilance centre in Indonesia is BPOM.
  </td>
  
  <td>
  8
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Spontaneous reporting is only those
  that are unexpected (Unexpected Adverse Reaction).
  </td>
  
  <td>
  9
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR is one of the contributors to
  the highest number of deaths in various countries.
  </td>
  
  <td>
  10
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Decreased absorption of omeprazole
  due to drug interactions with antacids does not need to be reported.
  </td>
  
  <td>
  11
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Incidents of side effects due to drug
  overdose or medication errors need to be reported.
  </td>
  
  <td>
  12
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  The discontinuation of the Albothyl
  product in 2018 and the subsequent call to improve the drug's indications so
  that it is not used for mouth ulcers are examples of pharmacovigilance
  efforts being implemented to protect the public from significant adverse drug
  effects.
  </td>
  
  <td>
  13
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  <td>
  Psychological
  </td>
  
  <td>
  Pharmacists in healthcare facilities
  play an essential role in pharmacovigilance activities.
  </td>
  
  <td>
  14
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Pharmacists in health service
  facilities must regularly update their knowledge regarding pharmacovigilance.
  </td>
  
  <td>
  15
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  If a drug side effect occurs in their
  practice, the pharmacist is not obliged to report it.
  </td>
  
  <td>
  16
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Pharmacists in health service
  facilities are the public's first reference in reporting AE/ADR.
  </td>
  
  <td>
  17
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  Pharmacists must receive special
  training regarding pharmacovigilance.
  </td>
  
  <td>
  18
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Spontaneous AE/ADR reporting must be
  done willingly or as part of professionalism.
  </td>
  
  <td>
  19
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Reporting and monitoring of AE/ADR
  will be beneficial for patients.
  </td>
  
  <td>
  20
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR that occur due to
  over-the-counter drugs/limited over-the-counter and over-the-counter drugs
  must also be reported.
  </td>
  
  <td>
  21
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  Reporting AE/ADR will add more
  insight regarding the side effects of drugs encountered in practice.
  </td>
  
  <td>
  22
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Reporting AE/ADR experienced by
  patients is a sign that their concerns are being taken seriously.
  </td>
  
  <td>
  23
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Spontaneous reporting of AE/ADR is
  part of pharmaceutical care.
  </td>
  
  <td>
  24
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR must be reported even if the
  impact does not result in hospitalization, life-threatening conditions,
  disability, or death.
  </td>
  
  <td>
  25
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  All adverse events/ESOs that occur as
  a result of drugs that have just received distribution permits and medicines
  that have been on the market for a long time must be reported.
  </td>
  
  <td>
  26
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  AE/ADR reporting must be done
  immediately, especially for dangerous or unexpected events (Unexpected
  Adverse Reaction).
  </td>
  
  <td>
  27
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  <td>
  Environment
  </td>
  
  <td>
  The pharmacist where I practice
  applies a regular shift work system.
  </td>
  
  <td>
  28
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  In one work shift, the pharmacist at
  my workplace practices according to the specified working hours.
  </td>
  
  <td>
  29
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  The pharmacists' working hours where
  I work follow the given workload.
  </td>
  
  <td>
  30
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  My workplace will give rewards/awards
  to pharmacists if they make innovations in their work or succeed in achieving
  specific targets.
  </td>
  
  <td>
  31
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Promotions at my workplace are carried
  out objectively based on the achievements and contributions of a pharmacist.
  </td>
  
  <td>
  32
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  The income I get from my workplace is
  enough for me because it matches my workload.
  </td>
  
  <td>
  33
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  My workplace will provide additional
  income if there is extra work or overtime provided
  </td>
  
  <td>
  34
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  The portion of work at my workplace
  is proportional enough to do other work without needing overtime.
  </td>
  
  <td>
  35
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I complete work while at work and
  never do work at home/outside of my working hours
  </td>
  
  <td>
  36
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  <td>
  Practice
  </td>
  
  <td>
  The frequency with which I encounter
  reports of drug side effects or adverse events from patients at work.
  </td>
  
  <td>
  37
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  The frequency with which the hospital
  where I work reports drug side effects or adverse events to the BPOM National
  Pharmacovigilance Center
  </td>
  
  <td>
  38
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  All drug side effects or adverse
  events reported by the patient are immediately reported to the unit head/head
  of pharmacy installation/pharmacist responsible for spontaneous reporting to
  BPOM.
  </td>
  
  <td>
  39
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  I document all reports of drug side
  effects or adverse events from patients, both unexpected and expected.
  </td>
  
  <td>
  40
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  I report and document all actions and
  interventions I provide to patients according to the patient's complaints.
  </td>
  
  <td>
  41
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  Suppose there is a complaint that a
  patient has a dry cough due to using the drug captopril. In that case, I will
  report it to the unit head/head of pharmacy installation/pharmacist
  responsible for spontaneous reporting to BPOM.
  </td>
  
  <td>
  42
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  Suppose there is a complaint that a
  patient experiences extrapyramidal syndrome due to the use of the drug
  metoclopramide. In that case, I will report it to the unit head/head of
  pharmacy installation/pharmacist responsible for spontaneous reporting to
  BPOM.
  </td>
  
  <td>
  43
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  Suppose there is an incident of
  decreased absorption of the drug omeprazole as a result of drug interactions
  with antacids. In that case, I will report it to the unit head/head of
  pharmacy installation/pharmacist responsible for spontaneous reporting to BPOM.
  </td>
  
  <td>
  44
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I carried out a causality analysis
  first with the doctor who provided therapy to the patient to ensure the
  causality of the side effects of the medication experienced by the patient.
  </td>
  
  <td>
  45
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  I include information in the form of reporting
  data, data on patients who submit complaints, complaints felt by patients,
  and data on suspected drugs in every report I submit to the head of the
  unit/head of the pharmacy installation/pharmacist responsible for spontaneous
  reporting to BPOM.
  </td>
  
  <td>
  46
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  I discussed with the doctor who
  provides therapy to treat patients who experience side effects from drugs.
  </td>
  
  <td>
  47
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I take my time at work to handle drug
  safety incident complaints from patients immediately.
  </td>
  
  <td>
  48
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I take the time to do documentation
  and report cases of drug side effects or adverse events encountered in
  patients.
  </td>
  
  <td>
  49
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I prioritize work related to patient
  safety while undergoing therapy.
  </td>
  
  <td>
  50
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I apply all points of clinical
  pharmacy services, including monitoring drug side effects (MESO) following
  the Minister of Health Regulations, where I practice.
  </td>
  
  <td>
  51
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I actively participate in the
  spontaneous reporting of drug side effects or adverse events as a form of professionalism
  and compliance with regulations.
  </td>
  
  <td>
  52
  </td>
  
  <td>
  Valid
  </td>
  
 </tr>
 <tr>
  
  <td>
  I have a spontaneous reporting
  account at e-meso.pom.go.id or the e-meso mobile smartphone application and
  operate it actively.
  </td>
  
  <td>
  53
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I provide a yellow form for
  spontaneous reporting of drug side effects to BPOM manually at my practice.
  </td>
  
  <td>
  54
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
 <tr>
  
  <td>
  I participated in multilevel
  pharmacovigilance training held by BPOM as the national pharmacovigilance
  centre.
  </td>
  
  <td>
  55
  </td>
  
  <td>
  Invalid*
  </td>
  
 </tr>
</table></table-wrap>

<p >* invalid item</p>
			</sec><sec>
			<title>CONCLUSION</title>
				<p >Evaluation
of validation results on knowledge question items found two invalid items and
four question items could not represent psychological variables. There are
three invalid items for environmental variables, and then for practice
variables, there are twelve invalid items. Thirty-four question items can still
be used to acquire further data.</p>
			</sec><sec>
			<title>ACKNOWLEDGMENT</title>
				<p >The author would like to
thank the directors of type C hospitals in Surabaya and Sidoarjo for allowing
questionnaires to be distributed within their facilities. Furthermore, all
pharmacists in type C hospitals were eager to fill out questionnaires and participate
in this study. The author also expresses gratitude to Universitas Airlangga's
Center of Excellence for Patient Safety and Quality, which assisted in funding
the research. Also, thanks to the Universitas Airlangga's Innovative Pharmacy
Practice and Integrated Outcome Research (INACORE) Group for providing
recommendations and advice on the manuscript's writing and content.</p>
			</sec><sec>
			<title>AUTHORS’ CONTRIBUTION</title>
				<p ><bold>Conceptualization</bold>: Favian Rafif Firdaus, Elida Zairina</p><p ><bold>Data curation</bold>: Favian Rafif Firdaus</p><p ><bold>Formal analysis</bold>: Favian Rafif Firdaus, Elida Zairina</p><p ><bold>Funding acquisition</bold>: -</p><p ><bold>Investigation</bold>: Favian Rafif Firdaus</p><p ><bold>Methodology</bold>: Elida Zairina</p><p ><bold>Project administration</bold>: Favian Rafif Firdaus</p><p ><bold>Resources</bold>: Elida Zairina</p><p ><bold>Software</bold>: -</p><p ><bold>Supervision</bold>: Yunita Nita, Catur Dian Setiawan, Elida Zairina</p><p ><bold>Validation</bold>: Elida Zairina</p><p ><bold>Visualization</bold>: -</p><p ><bold>Writing - original draft</bold>: Favian Rafif Firdaus</p><p ><bold>Writing - review &amp;
editing</bold>: Yunita Nita, Catur Dian Setiawan,
Elida Zairina</p>
			</sec><sec>
			<title>DATA AVAILABILITY</title>
				<p >None.</p>
			</sec><sec>
			<title>CONFLICT OF INTEREST</title>
				<p >There
are no conflicts of interest.</p>
			</sec><sec>
			<title>REFERENCES</title>
				<p >1.
Jose J, Al Rubaie MH, Al Ramimmy H, Varughese SS. Pharmacovigilance:
Basic concepts and an overview of the system in Oman. Sultan Qaboos Univ Med J.
2021;21(2):e161-3. DOI: 10.18295/squmj.2021.21.02.001; PMCID: PMC8219341; PMID: 34221460</p><p >2. Zhou N, Fang Z, Liang D, Lian J, Han H, Li R.
Hospital information system-based pharmacovigilance for elderly patients:
practices and results. J Pak Med Assoc. 2023;73(3):525–32. DOI: 10.47391/jpma.6428; PMID: 36932754</p><p >3. Katyal J, Arora E, Gupta YK. Impact of increased
focus on pharmacovigilance on knowledge and attitude towards adverse drug
reaction reporting among medical students in India. Int J Risk Saf Med.
2020;31(1):15–24. DOI: 10.3233/jrs-195012; PMID: 31594254</p><p >4. Asiamah M, Akuffo KO, Nortey P, Donkor N,
Danso-Appiah A. Spontaneous reporting of adverse drug reaction among health
professionals in Ghana. Arch Public Health. 2022;80(1):33. DOI: 10.1186/s13690-021-00783-1; PMCID: PMC8772084; PMID: 35057859</p><p >5. Yawson AA, Abekah-Nkrumah G, Okai GA, Ofori CG.
Awareness, knowledge, and attitude toward adverse drug reaction (ADR) reporting
among healthcare professionals in Ghana. Ther Adv Drug Saf.
2022;13:20420986221116468. DOI: 10.1177/20420986221116468; PMCID: PMC9364224; PMID: 35966898</p><p >6. Bahlol M, Bushell M, Khojah HMJ, Dewey RS.
Spontaneous adverse drug reaction reporting by community pharmacists:
preparedness and barriers. Saudi Pharm J. 2022;30(7):1052–9. DOI: 10.1016/j.jsps.2022.04.006; PMCID: PMC9315256; PMID: 35903525</p><p >7. Kobayashi T, Noda A, Obara T, Tsuchiya M,
Akasaka K, Yoshida M, et al. Knowledge, Attitudes, and Practice of Hospital
Pharmacists Regarding Pharmacovigilance and Adverse Drug Reaction Reporting in
Japan. Hosp Pharm. 2021;56(1):7–16. DOI: 10.1177/0018578719851455</p><p >8. Ampadu HH, Hoekman J, de Bruin ML, Pal SN,
Olsson S, Sartori D, et al. Adverse Drug Reaction Reporting in Africa and a
Comparison of Individual Case Safety Report Characteristics Between Africa and
the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Drug Saf.
2016;39(4):335–45. DOI: 10.1007/s40264-015-0387-4; PMCID: PMC4796322; PMID: 26754924</p><p >9. Kopciuch D, Zaprutko T, Paczkowska A, Ratajczak
P, Zielińska-Tomczak Ł, Kus K, et al. Safety of medicines—Pharmacists'
knowledge, practice, and attitudes toward pharmacovigilance and adverse drug
reactions reporting process. Pharmacoepidemiol Drug Saf. 2019;28(12):1543–51.
DOI: 10.1002/pds.4792; PMID: 31148344</p><p >10. Hailu AD, Mohammed SA. Adverse Drug Reaction
Reporting in Ethiopia: Systematic Review. Biomed Res Int. 2020;2020:8569314.
DOI: 10.1155/2020/8569314; PMCID: PMC7439161; PMID: 32851089</p><p >11. Bhattacharyya S, Kaur R, Kaur S, Ali SA. Validity
and reliability of a questionnaire: a literature review. Chron Dent Res. 2017;6(2):16-22.</p><p >12. Mohajan HK. Two Criteria for Good Measurements
in Research: Validity and Reliability. Ann Spiru Haret Univ Econom Ser.
2017;17(4):59-82. DOI: 10.26458/1746</p><p >13. Ramu P, Osman M, Mutalib NAA, Aljaberi MA, Lee
KH, Lin CY, et al. Validity and Reliability of a Questionnaire on the
Knowledge, Attitudes, Perceptions and Practices toward Food Poisoning among
Malaysian Secondary School Students: A Pilot Study. Healthcare. 2023;11(6):853.
DOI: 10.3390/healthcare11060853; PMCID: PMC10047946; PMID: 36981510</p><p >14. Radhakrishna RB. Tips for Developing and Testing
Questionnaires/Instruments. J Ext. 2007;45(1):25.</p><p >15. World Health Organization. The importance of
pharmacovigilance. Geneva: World Health Organization; 2002. p. 48.</p><p >16. Badan Pengawas Obat dan Makanan Republik
Indonesia. Buletin Berita MESO Juni 2023 Vol 41 No. 1. Jakarta: Badan Pengawas
Obat dan Makanan Republik Indonesia; 2023.</p><p >17.
Badan Pengawas Obat dan Makanan Republik Indonesia. Peraturan Badan
Pengawas Obat dan Makanan Nomor 15 Tahun 2022 tentang Penerapan
Farmakovigilans. Jakarta: Badan Pengawas Obat dan Makanan Republik Indonesia;
2022.</p><p >18.
Badan Pengawas Obat dan Makanan Republik Indonesia. Modul
Farmakovigilans Dasar: Project for Ensuring Drug and Food Safety. Jakarta:
Badan Pengawas Obat dan Makanan Republik Indonesia; 2020. Available from: https://e-meso.pom.go.id/web/useruploads/files/reference/5eaa2698c3abc_Modul%20Farmakovigilans%20Dasar.pdf</p><p >19.
Badan Pengawas Obat dan Makanan Republik Indonesia. Modul
Farmakovigilans untuk Tenaga Profesional Kesehatan: Project for Ensuring Drug
and Food Safety. Jakarta: Badan Pengawas Obat dan Makanan Republik Indonesia;
2020. Available from: https://e-meso.pom.go.id/web/useruploads/files/reference/5efb0dbc8d7eb_MODUL%20FARMAKOVIGILANS%20BAGI%20TENAGA%20PROFESIONAL%20KESEHATAN.pdf </p><p >20. Badan Pengawas Obat dan Makanan Republik
Indonesia. Lampiran – Daftar Produk yang Mengandung Policresulen Cairan Obat
Luar Konsentrat. Jakarta: Badan Pengawas Obat dan Makanan Republik Indonesia;
2018. Available
from: https://www.pom.go.id/storage/dat/20180215/Lampiran_penjelasan_Kabadan.pdf </p><p >21. Guest G. Using Guttman Scaling to Rank Wealth:
Integrating Quantitative and Qualitative Data. Field Methods.
2000;12(4):346-57. DOI: 10.1177/1525822X0001200406</p><p >22. Setiawan MH, Supriyadi, Bharati DAL. Analysis of
Instrument Development Recount Text Writing Test HOTS for Vocational High
School using Exploratory Factor Analysis (EFA). J Educ Sci Technol. 2022;8(1):74-86.
DOI: 10.26858/est.v8i2.25910</p><p >23. Trisnantoro L, Listyani E. Jumlah Rumah Sakit di
Indonesia Pertumbuhan Rumah Sakit Publik. Jakarta: Perhimpunan Rumah Sakit
Seluruh Indonesia; 2018. Available from: https://web.persi.or.id/analis-data/441-jumlah-rs-di-indonesia-pertumbuhan-rs-publik </p><p >24. Hertzog MA. Considerations in determining sample
size for pilot studies. Res Nurs Health. 2008;31(2):180–91. DOI: 10.1002/nur.20247; PMID: 18183564</p><p >25. Oluwatayo JA. Validity and Reliability Issues in
Educational Research. J Educ Soc Res. 2012;2(2):391-400.</p><p >26. Brown JD. Statistics corner: Questions and
answers about language testing statistics: Point-biserial correlation
coefficients. Shiken. 2001;4(3):13-7.</p><p >27. Santoso S. Analisis SPSS pada statistik
parametrik. Jakarta: Elex Media Komputindo; 2012.</p><p >28. Streiner DL. Starting at the beginning: An
introduction to coefficient alpha and internal consistency. J Pers Assess.
2003;80(1):99–103. DOI: 10.1207/s15327752jpa8001_18; PMID: 12584072</p><p >29. Basuki I, Hariyanto. Asesemen pembelajaran.
Bandung: Remaja Rosdakarya; 2014.</p><p >30. Surapranata S. Analisis, Validitas, Reliabilitas
dan Interpretasi Hasil Tes Implementasi Kurikulum 2004. Bandung: Remaja
Rosdakarya; 2009.</p><p >31. Roy R, Sukumar GM, Philip M, Gopalakrishna G.
Face, content, criterion and construct validity assessment of a newly developed
tool to assess and classify work–related stress (TAWS– 16). PLoS One.
2023;18(1):e0280189. DOI: 10.1371/journal.pone.0280189; PMCID: PMC9821462; PMID: 36608043</p><p >32. Perinetti G. StaTips Part VI: Bivariate
correlation. South Eur J Orthod Dentofac Res. 2019;6(1):2–5. DOI: 10.5937/sejodr6-21664</p><p >33. Bonett DG. Point-biserial correlation: Interval
estimation, hypothesis testing, meta-analysis, and sample size determination.
Br J Math Stat Psychol. 2020;73(Suppl 1):113–44. DOI: 10.1111/bmsp.12189; PMID: 31565811</p><p >34. Chan LL, Idris N. Validity and Reliability of
The Instrument Using Exploratory Factor Analysis and Cronbach’s alpha. Int J
Acad Res Bus Soc Sci. 2017;7(10):400-10. DOI: 10.6007/IJARBSS/v7-i10/3387</p><p >35. Purwanto. Instrumen penelitian sosial dan
pendidikan : pengembangan dan pemanfaatan. Yogyakarta: Pustaka Pelajar; 2007.</p><p >36. Bewick V, Cheek L, Ball J. Statistics review 7:
Correlation and regression. Crit Care. 2003;7(6):451-9. DOI: 10.1186/cc2401; PMCID: PMC374386; PMID: 14624685</p><p >37. Wu RMX, Zhang Z, Zhang H, Wang Y, Shafiabady N,
Wan W, et al. An FSV analysis approach to verify the robustness of the
triple-correlation analysis theoretical framework. Sci Rep. 2023;13(1):9621.
DOI: 10.1038/s41598-023-35900-3; PMCID: PMC10267157; PMID: 37316559</p><p >38. Sürücü L, Maslakçi A. Validity and Reliability
in Quantitative Research. Bus Manag Stud Int J. 2020;8(3):2694–726. DOI: 10.15295/bmij.v8i3.1540</p><p >39. Rusilowati A. Pengembangan Instrumen Penilaian.
Semarang: UNNES Press; 2014.</p><p >40. Hendryadi. Editorial Note: Uji Validitas Dengan
Korelasi Item-Total? J Manajemen Strategi Aplikasi Bisnis. 2021;4(1):315–20. DOI: 10.36407/jmsab.v4i2.404</p><p >41. Azwar S. Reliabilitas dan Validitas. 4th
ed. Yogyakarta: Pustaka Pelajar; 2012.</p><p >42. Slamet R, Wahyuningsih S. Validitas dan
Reliabilitas terhadap Instrumen Kepuasan Kerja. J Manajemen Bisnis Aliansi.
2022;17(2):51–8. DOI: 10.46975/aliansi.v17i2.428</p><p >43. Bolarinwa OA. Principles and Methods of Validity
and Reliability Testing of Questionnaires Used in Social and Health Science
Researches. Niger Postgrad Med J. 2015;22(4):195-201. DOI: 10.4103/1117-1936.173959; PMID: 26776330</p><p >44. Lakens D. Sample Size Justification. Collabra
Psychology. 2022;8(1):33267. DOI: 10.1525/collabra.33267</p><p >45. Jenn C. Designing a Questionnaire. Malays Fam
Physician. 2006;1(1):32-5.</p>
			</sec></body>
  <back>
    <ack>
      <p>The author would like to thank the directors of type C hospitals in Surabaya and Sidoarjo for allowing questionnaires to be distributed within their facilities. Furthermore, all pharmacists in type C hospitals were eager to fill out questionnaires and participate in this study. The author also expresses gratitude to Universitas Airlangga's Center of Excellence for Patient Safety and Quality, which assisted in funding the research. Also, thanks to the Universitas Airlangga's Innovative Pharmacy Practice and Integrated Outcome Research (INACORE) Group for providing recommendations and advice on the manuscript's writing and content.</p>
    </ack>
  </back>
</article>